USFDA Clears Dr. Reddy’s Facility

  Published 1 year ago

Dr. Reddy’s facility inspection by the USFDA closes with VAI status; the company is committed to addressing all inspection observations.

  • USFDA issued an Establishment Inspection Report (EIR) post-GMP audit; inspection formally closed under regulatory guidelines.
  • Two observations cited in the May 2025 inspection, Dr. Reddy’s, are to be resolved within the required timeline.
  • Q4FY25 profit rose 22% YoY to ₹1,594 crore; revenue up 20% at ₹8,506 crore; stock down 0.44%.

You might like these

Lupin & SUP Partner for Tiotropium DPI in China

India's Manufacturing Sales Surge in 2024-25

Syrma SGS Rises on Korean JV

L&T Bags Rs 1,000, Crore Bhavali PSP Order in Maharashtra

Taiwan Unveils $510B AI Plan

India Tightens Equity Derivatives Oversight

R Systems and Mavvrik Partner to Manage AI Costs

News that matters the most ⚡